DE602004021395D1 - Verfahren zur behandlung von hepatozellulärem karzinom - Google Patents

Verfahren zur behandlung von hepatozellulärem karzinom

Info

Publication number
DE602004021395D1
DE602004021395D1 DE602004021395T DE602004021395T DE602004021395D1 DE 602004021395 D1 DE602004021395 D1 DE 602004021395D1 DE 602004021395 T DE602004021395 T DE 602004021395T DE 602004021395 T DE602004021395 T DE 602004021395T DE 602004021395 D1 DE602004021395 D1 DE 602004021395D1
Authority
DE
Germany
Prior art keywords
zvegf3
hepatocellular carcinoma
mammal
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004021395T
Other languages
English (en)
Inventor
Thomas E Palmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of DE602004021395D1 publication Critical patent/DE602004021395D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
DE602004021395T 2003-07-25 2004-07-09 Verfahren zur behandlung von hepatozellulärem karzinom Active DE602004021395D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49004703P 2003-07-25 2003-07-25
PCT/US2004/021835 WO2005011742A1 (en) 2003-07-25 2004-07-09 Method of treating hepatocellular carcinoma

Publications (1)

Publication Number Publication Date
DE602004021395D1 true DE602004021395D1 (de) 2009-07-16

Family

ID=34115347

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004021395T Active DE602004021395D1 (de) 2003-07-25 2004-07-09 Verfahren zur behandlung von hepatozellulärem karzinom

Country Status (9)

Country Link
US (4) US20050191304A1 (de)
EP (1) EP1660135B1 (de)
JP (1) JP4709145B2 (de)
AT (1) ATE432716T1 (de)
CA (1) CA2529798C (de)
DE (1) DE602004021395D1 (de)
DK (1) DK1660135T3 (de)
ES (1) ES2326978T3 (de)
WO (1) WO2005011742A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6893637B1 (en) * 1999-10-21 2005-05-17 Zymogenetics, Inc. Method of treating fibrosis
NZ700274A (en) * 2012-04-24 2016-10-28 Thrombogenics Nv Anti-pdgf-c antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432673B1 (en) * 1998-12-07 2002-08-13 Zymogenetics, Inc. Growth factor homolog ZVEGF3
ES2312223T3 (es) * 1998-12-07 2009-02-16 Zymogenetics, Inc. Zvegf3 homologo de factor de crecimiento.
US6893637B1 (en) * 1999-10-21 2005-05-17 Zymogenetics, Inc. Method of treating fibrosis

Also Published As

Publication number Publication date
ES2326978T3 (es) 2009-10-22
CA2529798A1 (en) 2005-02-10
US20110052588A1 (en) 2011-03-03
US20090028865A1 (en) 2009-01-29
US20050191304A1 (en) 2005-09-01
US20070054858A1 (en) 2007-03-08
CA2529798C (en) 2014-09-16
JP4709145B2 (ja) 2011-06-22
JP2006528663A (ja) 2006-12-21
EP1660135A1 (de) 2006-05-31
WO2005011742A1 (en) 2005-02-10
DK1660135T3 (da) 2009-09-07
ATE432716T1 (de) 2009-06-15
EP1660135B1 (de) 2009-06-03

Similar Documents

Publication Publication Date Title
DK1638586T3 (da) Synergistisk sammensætning til behandling af diabetes mellitus
DE60234183D1 (de) Verwendung von methylnaltrexon zur behandlung von immunsuppression
DE69925024D1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
ATE314062T1 (de) Zusammensetzungen zur abgabe von cortisolantagonisten
IL178175A0 (en) Tamper resistant dosage form comprising an adsorbent and an adverse agent
DE60321929D1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE602005018043D1 (de) Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
ATE496892T1 (de) Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
IS8105A (is) Lyfjablanda sem felur í sér ónæmisbæli til að nota í meðhöndlun á húðsjúkdómum
ATE320803T1 (de) Verfahren zur behandlung von alzheimerschen krankheit
ATE364595T1 (de) Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
EA200800766A1 (ru) Ингибиторы pi3k для лечения эндометриоза
EA200700403A1 (ru) ТРИЦИКЛИЧЕСКИЕ δ-ОПИОИДНЫЕ МОДУЛЯТОРЫ
ATE394104T1 (de) Adenosin a2a rezeptor-antagonisten zur behandlung und vorbeugung von leberfibrose, zirrhose und fettleber
ATE465735T1 (de) Verwendung einer kombination von morphin und mindestens einem opiatantagonisten zur behandlung von opiatabhängigkeit und zur verhinderung des nicht-oralen opiatmissbrauchs bei opiatsüchtigen
WO2003051290A3 (en) Treating b-cell mediated diseases by modulating dr6 activity
DE602004021395D1 (de) Verfahren zur behandlung von hepatozellulärem karzinom
JP2003528919A5 (de)
WO2006002195A3 (en) Method of complexing a protein by the use of a dispersed system and proteins thereof
NO20053189L (no) HVC-kombinasjonsterapi.
DK1537132T3 (da) Salt af mortin-6-glucuronid
WO2006041769A3 (en) Methods for the treatment of substance abuse and addiction
ATE454153T1 (de) 5-ht4 antagonisten zur behandlung von herzversagen
WO2007062048A3 (en) Role of proteoglycans in drug dependence

Legal Events

Date Code Title Description
8364 No opposition during term of opposition